NC STATE UNIVERSITY

Characterizing, Navigating, and Modeling the Chemical Space Using Next-Generation Cheminformatics Methods

Denis Fourches, PhD

Department of Chemistry, Bioinformatics Research Center, North Carolina State University, USA www.fourches-laboratory.com











LIPITOR (atorvastatin)

World's best-selling drug of all time (\$125 billion over 15 years)



Competitive inhibitor of HMG-CoA reductase in liver



PDB code = 1HWK

Cheminformatics is becoming an essential element in the chemist's toolbox

Characterizing molecules' structural properties

Navigating the chemical space

Building predictive models

Screening virtual libraries

Prioritizing new compounds to be tested

experimentally



Thousands of molecular descriptors are available for organic compounds	
constitutional, topological, structural, antum mechanics based, fragmental, steric, pharmacophoric, geometrical, thermodynamical, conformational, etc.	
- Building of models using machine learning methods (NN, SVM, RF)	
- Validation of models according to numerous statistical procedures, and their applicability domains.	

0.613 0.380 -0.222 0.708 1.146 0.491 0.301 0.141 0.956 0.256 0.799 1.195 1.005

A

С

Cherkasov, Muratov, Fourches, et al. 2014, J Med Chem, 57(12), 4977-5010

qu



Cherkasov, Muratov, Fourches, et al. 2014, J Med Chem, 57(12), 4977-5010



Correct Classification Rate (CCR) for QSAR models discriminating sensitizers from non-sensitizers was 71–88% when evaluated on several external validation sets, within a broad AD, with positive (for sensitizers) and negative (for non-sensitizers) predicted rates of 85% and 79% respectively.

Alves, Muratov, Fourches, Strickland, Kleinstreuer, Andrade, Tropsha. Toxicol Appl Pharmacol. 2015 Apr 15;284(2):262-72.



Alves, Muratov, Fourches, Strickland, Kleinstreuer, Andrade, Tropsha. Toxicol Appl Pharmacol. 2015 Apr 15;284(2):273-80.

Curation of Chemogenomics Data



Fourches, Muratov, Tropsha. Nature Chemical Biology. 2015, 11, 535. Fourches, Muratov, Tropsha. JCIM. 2016, In Press.

Can any QSAR model, even if well validated, be applied to any molecule ?



Applicability Domain of a given QSAR model



Development of New Computational Tools Adapted to Hyper-Dimensional HTS data to Analyze Drugs' Polypharmacology



Visualizing and comparing chemical datasets using the ADDAGRA approach



D.Fourches and A.Tropsha. Using Graph Indices for the Analysis and Comparison of Chemical Datasets. Molecular Informatics, 2013, 32, 827–842.

ADDAGRA for the analysis of prediction outliers



ADDAGRA for the analysis of prediction outliers



Hybrid modeling using
descriptorsboth chemical and biological
Environ Health Perspect. 2011,119(3):364-70
Chem Res Toxicol. 2011, 24(8):1251-62





Low et al. CRT. 2013, 26(8):1199



Cheminformatics Approaches To Analyze the Similarity and the Effects of Environmental Chemical Mixtures



Cheminformatics Approaches To Analyze the Similarity and the Effects of Environmental Chemical Mixtures

CBRA Radial Plots Based on Both Chemical and Children's Exposures Similarity



Concept of Quantitative Structure-Exposure-Toxicity Relationships (QSETR)



Need to develop new modeling workflow ...

Molecular Docking of ERK2 Inhibitors



Fourches et al. J Chem Inf Model. 2013 Aug 26;53(8):1915-22.

ERK2 – Bad results with Glide 2015-1



pKi





pKi



Four

Mole

pKi

GPU-accelerated molecular dynamics simulations

Example: 1 ns simulation of ERK2 using Desmond 65Å*90Å*70Å, 42k atoms, explicit solvent (TIP3P water), step= 1 femtosecond



Up to 1 µs per day on high-end GPU workstations!

New MD-QSAR modeling approach



Computation of MD Descriptors



- 3D descriptors computed for all conformations sampled along ligand MD simulations
- MD descriptors were constructed by taking the mean and standard deviation of each 3D descriptor
 distribution for each ligand:

7 6 5

$$\bar{x}_i = \frac{\sum_{j=1}^n x_{ij}}{n}$$

$$s_i = \sqrt{\frac{\sum_{j=1}^n (x_{ij} - \bar{x})^2}{n-1}}$$

NC STATE UNIVERSITY

Chemical Descriptors Associated with Ligand Activity

Dataset: 87 ERK2 kinase inhibitors; pKi ranging from 4.6 to 9



Descriptor Set Distributions



- Compounds were classified as
 - Active : pKi >= 7.5
 - Inactive : pKi < 7.5</p>
- For the 3D and MD descriptors, clear difference in the profiles of active and inactive compounds.
- For MACCS and 2D descriptors, the difference in active and inactive profiles is less apparent

NC STATE UNIVERSITY

Ash and Fourches. JCIM 2017. Under Review

Hierarchical Clustering of ERK2 Ligands

Using 2D and MD fingerprints

MACCS Fingerprints





Cophenetic correlation coefficient: **0.89**

Cophenetic correlation coefficient: **0.74**

NC STATE UNIVERSITY

pki

6

5

Ash and Fourches. JCIM 2017. Under Review

Characterizing the MD Chemical Space of ERK2 Inhibitor Conformations



Ash and Fourches. JCIM 2017. Under Review

NC STATE UNIVERSITY

pKi



Fourches D, Pu D, Tropsha A. Comb Chem High Throughput Screen. 2011 Fourches et al. Nanotoxicology, 2015, In Press.



QNAR Modeling of Carbon Nanotubes

In 2008, Zhou et al^{*} published *in vitro* protein binding, acute toxicity and immune toxicity assays for 84 Carbon NanoTubes (CNTs) decorated with different surface modifiers.



*Zhou et al. Nano Lett., Vol. 8, No. 3, 2008

Computer-aided design of novel carbon nanotubes with desired biological properties (in collaboration with Dr. Bing Yan, St. Jude Children's Research Hospital)



Fourches et al. Nanotoxicology 2016 In Press.



$ \begin{array}{ c c c c c c c c c c } \hline CNTID & II-1 & II-2 & II-3 & II-4 & II-5 & II-6 & II-7 & II-8 & II-9 & II-10 \\ \hline Average cell viability (%) & 58 & 61 & 61 & 56 & 58 & 65 & 68 & 72 & 68 & 59 \\ \hline Standard Deviation & 5 & 3 & 3 & 3 & 2 & 10 & 6 & 7 & 3 & 6 \\ (%) & 5 & 3 & 3 & 3 & 2 & 10 & 6 & 7 & 3 & 6 \\ \hline CNTID & I-1 & II-1 & II-12 & II-3 & II-14 & II-15 & II-16 & II-17 & II-18 & II-19 & II-20 \\ \hline CNTID & II-11 & II-12 & II-13 & II-14 & II-15 & II-16 & II-17 & II-18 & II-19 & II-20 \\ \hline Average cell viability (%) & 39 & 49 & 46 & 49 & 52 & 41 & 51 & 49 & 5 & 50 \\ \hline Standard Deviation (%) & 39 & 49 & 46 & 49 & 52 & 41 & 51 & 49 & 5 & 50 \\ \hline CNTID & II-1 & I & 1 & 1 & 1 & 1 & 1 & 1 & 1 & 1 & $	[D Norm	al		11-	8 CN	I		11-	-11 C	;N I		
Average cell viability (%) 58 61 61 56 58 65 68 72 63 5 Standard Deviation (%) 5 3 3 3 2 10 66 7 3 6 Experiment (%) 0		CNTID	II-1	II-2	II-3	II-4	II-5	II-6	II-7	11-8) II	-9	II-10
Standard Deviation (%) 5 3 3 3 2 10 6 7 3 6 Experiment Predicted 0 </td <td>Av</td> <td>erage cell viability (%)</td> <td>58</td> <td>61</td> <td>61</td> <td>56</td> <td>58</td> <td>65</td> <td>68</td> <td>72</td> <td>6</td> <td>8</td> <td>59</td>	Av	erage cell viability (%)	58	61	61	56	58	65	68	72	6	8	59
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	St	andard Deviation (%)	5	3	3	3	2	10	6	7	3	3	6
Predicted 0 <th0< td=""><td></td><td>Experiment</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>(</td><td>0</td><td>0</td></th0<>		Experiment	0	0	0	0	0	0	0	0	(0	0
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		Predicted	0	0	0	0	0	0	0	0	(0	0
Average cell viability (%) 39 49 46 49 52 41 51 49 5< 50 Standard Deviation (%) 9 8 7 5 8 11 5 9 1 1 Experiment (%) 1 1 1 1 0 1		CNTID	II-11	II-12	II-13	II-14	II-15	II-16	II-17	II-1	8 II-	19	II-20
Standard Deviation (%) 9 8 7 5 8 11 5 9 $1 \cdot 1$ 10 Experiment Predicted 1 1 1 1 1 0 1 00 1 00 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1	Av	erage cell viability (%)	39	49	46	49	52	41	51	49	5	5	50
Experiment Predicted111110101010101CNT IDII-21II-22II-23II-23II-25II-26II-26II-27II-28II-29II-30Average protein binding (F0/F1)1.771.781.871.761.822.301.742.001.672.33Standard Deviation0.050.060.020.030.020.020.020.010.060.02Experiment000000000000Predicted000000000000Average protein binding (F0/F1)3.402.281.33II-34II-35II-36II-37II-38II-39II-9Average protein binding (F0/F1)3.402.282.042.222.172.952.082.252.652.24Average protein binding (F0/F1)3.402.282.042.222.172.952.082.252.652.14Average protein binding (F0/F1)3.402.282.042.222.172.952.082.252.652.14Average protein binding (F0/F1)3.402.181111111Average protein binding (F0/F1)3.402.282.042.222.172.952.08 </td <td>St</td> <td>andard Deviation (%)</td> <td>9</td> <td>8</td> <td>7</td> <td>5</td> <td>8</td> <td>11</td> <td>5</td> <td>9</td> <td>1</td> <td>1</td> <td>10</td>	St	andard Deviation (%)	9	8	7	5	8	11	5	9	1	1	10
Predicted11		Experiment	1	1	1	1	0	1	0	1		0	0
CNT IDII-21II-22II-23II-24II-25II-26II-27II-28II-29II-30Average protein binding (F0/F1)1.771.781.871.761.822.301.742.001.672.33Standard Deviation0.050.060.020.030.020.020.020.010.060.02Experiment00000010101Predicted00000000000CNT IDII-31II-32II-33II-34II-35II-36II-37II-38II-39II-39Average protein binding (F0/F1)3.402.282.042.222.172.952.082.252.652.24Standard Deviation0.030.050.080.010.040.000.020.050.1111Average protein binding (F0/F1)3.402.282.042.222.172.952.082.252.652.24Standard Deviation0.030.050.080.010.040.000.020.050.111111Experiment111111111111Predicted111111111111		Predicted	1	1	1	1	1	1	1	1		1	1
Average protein binding (F0/F1) 1.77 1.78 1.87 1.76 1.82 2.30 1.74 2.00 1.67 2.33 Standard Deviation 0.05 0.06 0.02 0.03 0.02 0.02 0.02 0.01 0.06 0.02 Experiment 0 0 0 0 0 1 0 1 0 1 0 1 Predicted 0		CNTID	II-21	II-22	II-23	II-24	II-25	II-26	II-27	II-28	II-29	II-30)
Standard Deviation 0.05 0.06 0.02 0.03 0.02 0.02 0.01 0.06 0.02 Experiment 0 0 0 0 0 1 0 1 0 1 0 1 Predicted 0		Average protein binding (F0/F1)	1.77	1.78	1.87	1.76	1.82	2.30	1.74	2.00	1.67	2.33	3
Experiment 0 0 0 0 1 0 1 0 1 Predicted 0		Standard Deviation	0.05	0.06	0.02	0.03	0.02	0.02	0.02	0.01	0.06	0.02	
Predicted 0		Experiment	0	0	0	0	0	1	0	1	0	1	
CNTID II-31 II-32 II-33 II-34 II-35 II-36 II-37 II-38 II-39 II-9 Average protein binding (F0/F1) 3.40 2.28 2.04 2.22 2.17 2.95 2.08 2.25 2.65 2.24 Standard Deviation 0.03 0.05 0.08 0.01 0.04 0.00 0.02 0.05 0.11 Experiment 1 <td></td> <td>Predicted</td> <td>о</td> <td>о</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>о</td> <td>0</td> <td>0</td> <td>0</td> <td></td>		Predicted	о	о	0	0	0	0	о	0	0	0	
Average protein binding (F0/F1) 3.40 2.28 2.04 2.22 2.17 2.95 2.08 2.25 2.65 2.24 Standard Deviation 0.03 0.05 0.08 0.01 0.04 0.00 0.02 0.06 0.05 0.11 Experiment 1		CNTID	II-31	II-32	II-33	II-34	II-35	II-36	II-37	II-38	II-39	11-9	
Standard Deviation 0.03 0.05 0.08 0.01 0.04 0.00 0.02 0.06 0.05 0.11 Experiment 1		Average protein binding (F0/F1)	3.40	2.28	2.04	2.22	2.17	2.95	2.08	2.25	2.65	2.24	ŧ
Experiment 1 <th1< td=""><td></td><td>Standard Deviation</td><td>0.03</td><td>0.05</td><td>0.08</td><td>0.01</td><td>0.04</td><td>0.00</td><td>0.02</td><td>0.06</td><td>0.05</td><td>0.11</td><td></td></th1<>		Standard Deviation	0.03	0.05	0.08	0.01	0.04	0.00	0.02	0.06	0.05	0.11	
Predicted 1 1 1 1 1 1 1 1 1 1		Experiment	1	1	1	1	1	1	1	1	1	1	
		Predicted	1	1	1	1	1	1	1	1	1	1	



All rationally prioritized, synthesized, and tested CNTs predicted as non-toxic were confirmed experimentally.



synthesized, and tested CNTs predicted as toxic were confirmed experimentally



Fourches et al. Nanotoxicology 2016 In Press.

	Experiment	0	0	0	0	0		0	1	0	-1
	Predicted	0	0	0	0	0	0	0	o	0	0
	CNTID	II-31	II-32	II-33	II-34	II-35	II-36	II-37	II-38	II-39	II-9
	Average protein binding (F0/F1)	3.40	2.28	2.04	2.22	2.17	2.95	2.08	2.25	2.65	2.24
S	Standard Deviation	0.03	0.05	0.08	0.01	0.04	0.00	0.02	0.06	0.05	0.11
	Experiment	1	1	1	1	1	1	1	1	1	1
	Predicted	1	1	1	1	1	1	1	1	1	1



QNAR models for the enhanced set of f-CNTs

Classification Models (LOO)

Continuous Models (LOO)

Cytotoxicity	Threshold	Sensitivity		Specific	Accuracy	
Random Forest	0.45	79.25%	42	62.00%	31	70.87%
SVM-C Model	0.45	74.40%	41	56.00%	28	66.99%

Cyotoxicity Regression Tree Consensus Model Predictions



HLA-induced drug adverse effects

Small molecule drugs bind specifically to certain type of HLA proteins.





Range of "self" peptides able to bind the given HLA type is modified

Immune reaction

HLA proteins as important offtargets
Need predictive models to assess HLA-induced ADR



Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles.



Goldstein et al. Nature Communications. 2014, 5:4757

GWAS +

Docking

Homology model of HLA-B39

Molecular Docking Study at HLA-B*57:01

Develop a virtual screening model using molecular docking at the HLA-B*57:01 variant using three X-ray crystals of abacavir bound to HLA-B*57:01.



Van Den Driessche et al. 2016, J. Cheminformatics. Under Review.

Summary



- Cheminformatics is becoming mandatory in all projects involving the curation, integration, characterization, analysis, testing, modeling, visualization, screening of chemicals.
- The skyrocketing amount of freely-available data in the public domain is boosting the development of new cheminformatics approaches to fully exploit that data, especially when it comes to chemical risk assessment and *in silico* toxicity predictions.
- New methods such as MD-QSAR or QSETR are poised to boost the prediction performances of cheminformatics predictors.
- Structure-based docking and pan-target screening have never been so relevant for chemical risk assessment, especially for key targets such as ER, AhR, or HLA.

Acknowledgements

Lab members

George Van Den Driessche Jeremy Ash Melaine Kuenemann, PhD Ryan Lougee Phyo Phyo Kyaw Zin Bethany Cook

Funding

NCSU CFEP Program RISF CMI

NC STATE UNIVERSITY

dfourch @ncsu.edu www.fourches-laboratory.com Chancellor's Faculty Excellence Program